Just weeks after throwing in the towel on one of three late-stage studies of the rheumatoid arthritis drug tabalumab, Eli Lilly ($LLY) has opted to dump the remaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback